Screening, identification, and experimental validation of SUMOylation biomarkers in Parkinson’s disease
SUMO3 and SEH1L were identified as novel biomarkers for PD, offering potential targets for early diagnosis and therapy in PD.
Authors
- Yifo Wei
- Yue Yu (ORCID: https://orcid.org/0009-0004-6217-7124)
- Weizheng Ran
- Wanyi Dang (ORCID: https://orcid.org/0000-0001-6097-8367)
- Xiaoyan Wang (ORCID: https://orcid.org/0000-0001-5568-2131)
- Lu Chen (ORCID: https://orcid.org/0000-0002-5701-9306)
- Jia Yao (ORCID: https://orcid.org/0000-0002-8278-1917)
- Fan Liu (ORCID: https://orcid.org/0000-0002-0071-2177)
- Zhigang Chen (ORCID: https://orcid.org/0000-0002-8774-5894)
- Xinning Zhang (ORCID: https://orcid.org/0000-0002-3617-3582)
- Fengchun Lv
- Rena C. Zuo
Institutions
- Beijing University of Chinese Medicine (CN)
- Chinese PLA General Hospital (CN)
- Shaanxi Provincial Hospital of Traditional Chinese Medicine (CN)
- Shaanxi University of Chinese Medicine (CN)
Publication Details
- Journal
- Hereditas
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1186/s41065-025-00525-1
- Citations
- 1
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Strong
- National Natural Science Foundation of China
- Xi'an Municipal Bureau of Science and Technology
- Shaanxi Provincial Science and Technology Department
- Shaanxi University of Chinese Medicine